Vertex appoints ex-Boston Scientific CFO Daniel Brennan to board; board expands to 11 members

VERTEX PHARMACEUTICALS INC / MA

Daniel Brennan appointed to Vertex's board of directors on October 20, 2026, expanding the board from ten to eleven members.
Brennan also joins the Audit and Finance Committee; he retired in June 2025 as EVP and CFO of Boston Scientific, where he served from January 2014.
Brennan sits on boards of Waters Corporation (since November 2022) and Madrigal Pharmaceuticals (since August 2025); previously on Nuance's board until its 2022 Microsoft acquisition.
Received a $400,000 restricted stock unit award upon joining, vesting in October 2027; Vertex reports no Item 404(a) related-party transactions.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.